CVS vs. MDGL: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CVS and MDGL, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CVS | MDGL |
|---|---|---|
| Company Name | CVS Health Corporation | Madrigal Pharmaceuticals, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 101.04 billion USD | 12.38 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | February 21, 1973 | February 6, 2007 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CVS and MDGL by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CVS | MDGL |
|---|---|---|
| 5-Day Price Return | 0.35% | 6.72% |
| 13-Week Price Return | 13.43% | 43.09% |
| 26-Week Price Return | 28.61% | 79.17% |
| 52-Week Price Return | 43.38% | 67.92% |
| Month-to-Date Return | -0.44% | 26.33% |
| Year-to-Date Return | 73.33% | 71.50% |
| 10-Day Avg. Volume | 6.62M | 0.52M |
| 3-Month Avg. Volume | 7.69M | 0.38M |
| 3-Month Volatility | 23.53% | 44.24% |
| Beta | 0.48 | -1.08 |
Profitability
Return on Equity (TTM)
CVS
0.62%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
CVS’s Return on Equity of 0.62% is in the lower quartile for the Health Care Providers & Services industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
MDGL
-41.50%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
MDGL has a negative Return on Equity of -41.50%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
CVS
0.12%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
Falling into the lower quartile for the Health Care Providers & Services industry, CVS’s Net Profit Margin of 0.12% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
MDGL
-39.04%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
MDGL has a negative Net Profit Margin of -39.04%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
CVS
1.49%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
CVS’s Operating Profit Margin of 1.49% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
MDGL
-41.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
MDGL has a negative Operating Profit Margin of -41.89%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | CVS | MDGL |
|---|---|---|
| Return on Equity (TTM) | 0.62% | -41.50% |
| Return on Assets (TTM) | 0.18% | -26.18% |
| Net Profit Margin (TTM) | 0.12% | -39.04% |
| Operating Profit Margin (TTM) | 1.49% | -41.89% |
| Gross Profit Margin (TTM) | 13.88% | 95.25% |
Financial Strength
Current Ratio (MRQ)
CVS
0.83
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
CVS’s Current Ratio of 0.83 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
MDGL
3.44
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
MDGL’s Current Ratio of 3.44 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CVS
0.90
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
CVS’s Debt-to-Equity Ratio of 0.90 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MDGL
0.54
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
MDGL’s Debt-to-Equity Ratio of 0.54 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
CVS
3.08
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
CVS’s Interest Coverage Ratio of 3.08 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
MDGL
-163.11
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
MDGL has a negative Interest Coverage Ratio of -163.11. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | CVS | MDGL |
|---|---|---|
| Current Ratio (MRQ) | 0.83 | 3.44 |
| Quick Ratio (MRQ) | 0.63 | 3.14 |
| Debt-to-Equity Ratio (MRQ) | 0.90 | 0.54 |
| Interest Coverage Ratio (TTM) | 3.08 | -163.11 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CVS
3.43%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.43%, CVS offers a more attractive income stream than most of its peers in the Health Care Providers & Services industry, signaling a strong commitment to shareholder returns.
MDGL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MDGL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
CVS
74.62%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
CVS’s Dividend Payout Ratio of 74.62% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
MDGL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MDGL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | CVS | MDGL |
|---|---|---|
| Dividend Yield (TTM) | 3.43% | 0.00% |
| Dividend Payout Ratio (TTM) | 74.62% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
CVS
210.61
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
At 210.61, CVS’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Health Care Providers & Services industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
MDGL
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for MDGL is currently unavailable.
Price-to-Sales Ratio (TTM)
CVS
0.25
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
In the lower quartile for the Health Care Providers & Services industry, CVS’s P/S Ratio of 0.25 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
MDGL
16.73
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
MDGL’s P/S Ratio of 16.73 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
CVS
1.31
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
CVS’s P/B Ratio of 1.31 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
MDGL
16.34
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
MDGL’s P/B Ratio of 16.34 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | CVS | MDGL |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 210.61 | -- |
| Price-to-Sales Ratio (TTM) | 0.25 | 16.73 |
| Price-to-Book Ratio (MRQ) | 1.31 | 16.34 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.70 | 163.10 |